AMA
AMERICAN MEDICAL ASSOCIATION

WMA

North American Regional Meeting on the Declaration of Helsinki

Aug. 15–16
Westin Washington, D.C. City Center

Agenda

Thursday, Aug. 15

7:30–8:30 a.m.	**Breakfast buffet available** *National C and West*
8–9:30 a.m.	**Registration** *National Ballroom Foyer*
9–9:20 a.m.	**Opening remarks** *National Ballroom* **Lujain Alqodmani, MD,** president, World Medical Association **Robert M. Califf, MD,** commissioner, food and drug administration (remote)
9:20–10 a.m.	**The proposed revision: A review** **Jack Resneck Jr., MD,** chair, Declaration of Helsinki (DoH) Revision Workgroup
10–10:30 a.m.	**Break**
10:30 a.m.–2:30 p.m.	**The proposed revision: Challenges and changes** **Description:** This extended session will feature four parts showcasing expert perspectives on a prominent topic of the DoH revision.
10:30 a.m.–noon	**Challenges and changes: Focus Session Part 1, Vulnerability, community engagement and global justice (panel presentation)** SPEAKERS **Lainie Ross, MD, PhD,** dean, chair and professor, University of Rochester **Nancy Kass, ScD,** Phoebe R. Berman Professor of Bioethics and Public Health, Johns Hopkins University RESPONDENT
Noon–1 p.m.	**Buffet lunch for all attendees** *National Ballroom C and West*
1–1:30 p.m.	**Challenges and changes: Part 2, Data research and privacy** SPEAKER **Jay Shaw, PT, PhD,** research director, AI, Ethics & Health, University of Toronto RESPONDENT **Kayte Spector-Bagdady, JD, MBe,** interim co-director, Center for Bioethics and Social Sciences in Medicine, University of Michigan

1:30–2 p.m.

Challenges and changes: Part 3, Public health emergencies and compassionate use

SPEAKER

Arthur Caplan, PhD, Mitty Professor of Bioethics, New York University (via Zoom)

RESPONDENT

Jonathan Moreno, PhD, Silfen Professor of Ethics, University of Pennsylvania

2–2:30 p.m.

Challenges and changes: Part 4, Scientific and social value

SPEAKER

Gustavo Ortiz Millán, PhD, Universidad Autónoma de México

RESPONDENT

Barbara Bierer, MD, Multi-Regional Trials Center, Brigham and Women's Hospital, Harvard

2:30–3 p.m.

Break

3–4:15 p.m.

Health research ethics across North America

Description: This session represents researchers, ethics committee members and patient advocates from different geographies across North America. Each panelist will discuss what ethical guidance and protections they find particularly helpful, what issues they continue to struggle with, and where the health research ethics efforts are needed next. If applicable, speakers will consider these topics through the DoH: what aspects of the DoH have been particularly relevant or helpful to their work; what proposed DoH revisions are they pleased to see; what challenges do they foresee in implementing and interpreting the DoH; and how could future iterations of the DoH continue to further develop ethical guidance.

MODERATOR

Amber Comer, PhD, JD, director, Ethics Policy, American Medical Association

SPEAKERS

Patricio J. S. Doherty, head, National Bioethics Committee of Mexico

Missy Heidelberg, BS, MBE, global bioethics lead, Takeda Pharmaceuticals

Peter Pronovost, MD, PhD, chief quality and clinical transformation officer, University Hospitals, Cleveland

Susan Marlin, president and CEO, Clinical Trials Ontario

4:15–4:30 p.m.

Closing remarks

Jack Resneck Jr., MD, chair, Declaration of Helsinki Revision Workgroup

6 p.m.

Reception for all attendees

National Academy of Sciences—bus transportation will be provided

7 p.m.

Monuments by Moonlight Walking Tour

For those who registered, tour will leave from the National Academy of Sciences and return to the Academy at 8:45 p.m. for transportation back to the hotel.

Friday, Aug. 16

8–9 a.m.

Breakfast buffet available
National Ballroom West and C

8 a.m.

Registration available
National Ballroom Foyer

9–9:15 a.m.

Opening Remarks

Bruce Scott, MD, president, American Medical Association

Major General (ret.) Paul Friedrichs, MD, director, Office of Pandemic Preparedness and Response Policy

9:15–10:15 a.m.

The U.S. government and health research ethics

Description: This educational learning panel will provide a window into how the U.S. government approaches health research ethics. Each panelist will address their agency's unique role and responsibilities in helping to set and implement ethical standards, as well as how the three agencies work together to do so. Speakers can also address what ethical issues have been particularly important to the U.S. government, both recently and historically, and what ethical issues will be increasingly poignant in the future.

MODERATOR

Bruce Scott, MD, president, American Medical Association

SPEAKERS

Julie Kaneshiro, MA, acting director, Office for Human Research Protections, U.S. Dept. of Health and Human Services

Hilary Marston, MD, MPH, chief medical officer, U.S. Food and Drug Administration

Adam Berger, PhD, division director, Clinical and Healthcare Research Policy, Office of Science Policy, Office of the Director, National Institutes of Health

10:15–10:45a.m.

Break

10:45–11:45 a.m.	**Maximizing impact: Communications, advocacy and implementation** **Description:** This session will focus on next steps to increase awareness and implementation of the revised DoH. Topics will include: 1) coordination with partners and aligning other guidelines, such as the Council for International Organizations of Medical Sciences' International Ethical Guidelines for Health-related Research Involving Humans; 2) communicating with research participants and patients; and 3) the approach and experience of countries that have adopted the DoH as codified law. MODERATOR **Lujain Alqodmani, MD,** president, World Medical Association SPEAKERS **Otmar Kloiber, MD,** secretary-general, World Medical Association **Hans Van Delden,** professor, University Medical Center **Lara Bloom,** board member, International Alliance of Patient Organizations **Chieko Kurihara, BA,** ethics working group, International Federation of Associations of Pharmaceutical Physicians
11:45 a.m.–noon	**Closing remarks** **Jack Resneck Jr., MD,** chair, Declaration of Helsinki Revision Workgroup
Noon–1 p.m.	**Buffet lunch for all attendees** *National Ballroom C and West*
2:15 p.m.	**Optional visit to the National African American Museum of History and Culture** *1400 Constitution Ave.* *AMA has secured 75 tickets for a 2:15 p.m. entry.*



Lujain Alqodmani, MD

President
World Medical Association

Dr. Lujain Alqodmani, a global health and medical professional, currently holds the prestigious position of President at the World Medical Association (WMA) for the term 2023-2024. Renowned for her leadership, she spearheads the WMA's initiatives, advocating for global healthcare excellence and ethical medical practices worldwide.

Alongside her role as WMA President, Lujain serves as the Director of Global Action and Project Portfolio at EAT, leveraging her expertise to steer the implementation of strategic goals and oversee impactful projects at EAT.

Previously, Dr. Alqodmani contributed significantly to various health sectors. Her experiences range from serving as an emergency physician in Kuwait to holding vital roles such as the co-chair of the WMA Environment Caucus and the International Relations Director at Kuwait Medical Association. Moreover, she held influential positions at Women in Global Health and the International Federation of Medical Students' Associations (IFMSA), where she represented the Eastern Mediterranean Region and led crucial internal affairs portfolios.

With a medical degree from Kuwait University and a Master's in international healthcare management, economics, and policy from SDA Bocconi, Lujain Alqodmani remains dedicated to elevating healthcare standards worldwide.

Adam Berger, PhD

Division Director
Clinical and Healthcare Research Policy
Office of Science Policy
Office of the Director, National Institutes of Health

Adam Berger is the Director of the Division of Clinical and Healthcare Research Policy at the NIH Office of Science Policy, Office of the Director. In this role, Adam oversees a wide range of policy issues related to clinical trials, biospecimen research, privacy, bioethics and human research participant protections, and translation of biomedical discoveries. Prior to joining NIH, Adam was part of the personalized medicine staff at the FDA where he addressed a wide range of policy and regulatory issues related to precision medicine, next generation sequencing, real world evidence, and digital health.

Adam also previously served as a Senior Fellow to the Secretary of Health and Human Services, overseeing the development and implementation of the Precision Medicine Initiative (PMI). In this role, he served as the main liaison between and representative of HHS to the White House and other United States Government Departments involved in the PMI. Prior to working in government, Adam was a Senior Program Officer and Director of the Roundtable on Translating Genomic-Based Research for Health in the Board on Health Sciences Policy at the Institute of Medicine, now the National Academy of Medicine.

Adam received his doctorate from Emory University in Biochemistry, Cell and Developmental Biology and his B.S. in Molecular Genetics from The Ohio State University. He completed his postdoctoral training at the National Cancer Institute of the NIH.



Barbara E. Bierer, MD

Professor of Medicine
Harvard Medical School

Barbara E. Bierer, M.D., a hematologist-oncologist, is Professor of Medicine at Harvard Medical School and the Brigham and Women's Hospital (BWH). Dr. Bierer co-founded and now leads the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center, www.mrctcenter.org), a collaborative effort to improve standards for the planning and conduct of international clinical trials to harmonize policies for and approaches to clinical trial regulation. In addition, she is the Director of the Regulatory Foundations, Ethics, and the Law program at the Harvard Clinical and Translational Science Center. She is the Director and PI of SMART IRB (www.SMARTIRB.org), a national effort to align single site IRB review of multi-site trials. She serves as Faculty in the Center for Bioethics, Harvard Medical School, and as Affiliate Faculty in the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. From 2003 – 2014, Dr. Bierer served as Senior Vice-President, Research at the Brigham and Women's Hospital (BWH). During her tenure, Dr. Bierer founded and served as Executive Sponsor of the Brigham Research Institute and the Brigham Innovation Hub (iHub), a focus for entrepreneurship and innovation in healthcare. She has authored over 300 publications.

Dr. Bierer received a B.S. from Yale University and an M.D. from Harvard Medical School.

Robert M. Califf, MD

Commissioner of Food and Drugs
U.S. Food and Drug Administration (FDA)

Dr. Robert M. Califf was confirmed as the 25th Commissioner of Food and Drugs.

As Commissioner, Dr. Califf oversees the full breadth of the FDA portfolio and execution of the Federal Food, Drug, and Cosmetic Act and other applicable laws. This includes assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices; the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation; and the regulation of tobacco products.

Dr. Califf has had a long and distinguished career as a physician, researcher, and leader in the fields of science and medicine. He is a nationally recognized expert in cardiovascular medicine, health outcomes research, health care quality, and clinical research, and a leader in the growing field of translational research, which is key to ensuring that advances in science translate into medical care.

This is Dr. Califf's second stint as Commissioner. He also served in 2016 as the 22nd Commissioner. Before assuming the position at that time, he served as the FDA's Deputy Commissioner for Medical Products and Tobacco.

Prior to rejoining the FDA in 2022, Dr. Califf was head of medical strategy and Senior Advisor at Alphabet Inc., contributing to strategy and policy for its health subsidiaries Verily Life Sciences and Google Health. He joined Alphabet in 2019, after serving as a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and was the founding director of the Duke Clinical Research Institute.

Dr. Califf is a graduate of Duke University School of Medicine. He completed a residency in internal medicine at the University of California, San Francisco and a fellowship in cardiology at Duke.

Arthur Caplan, PhD

Drs. William F and Virginia Connolly Mitty Professor Founding Head of the Division of Medical Ethics
NYU School of Medicine

Prior to coming to NYU School of Medicine, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. Caplan has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of Pittsburgh, and Columbia University. He received his PhD from Columbia University and holds eight honorary degrees from colleges, universities and medical schools.

Caplan has served since 2015 as the co-chairperson of the Compassionate Use Advisory Committee (CompAC), an independent group of internationally recognized medical experts, bioethicists and patient representatives which advises Johnson & Johnson's Janssen Pharmaceuticals about requests for compassionate use of some of its investigational medicines. Dr. Caplan is a regular commentator on bioethics and health care issues for WebMD/Medscape, WGBH radio in Boston, WOR radio in New York City and KNX-CBS radio, Los Angeles and appears frequently as a guest and commentator on various other national and international media outlets. Dr. Caplan is the recipient of many awards and honors including the McGovern Medal of the American Medical Writers Association and the Franklin Award from the City of Philadelphia. During the Covid-19 pandemic, he co-directed an advisory group on sports and recreation for the US Conference of Mayors, created a national working group on coronavirus vaccine challenge studies, developed an ethical framework for distributing drugs and vaccines for J&J, helped develop rationing policies for NYU LMC and many other health systems, and was a member of the WHO advisory committee on Covid, ethics and experimental drugs/vaccines. In 2024 he was honored as the mentor of the year by the NYUGSOM Department of Population Health.

Amber R. Comer, PhD, JD

Director, ethics policy and secretary, Council of Ethical and Judicial Affairs
American Medical Association

Amber Comer, PhD, JD is the Director of Ethics Policy and the Secretary of the Council of Ethical and Judicial Affairs at the American Medical Association. Additional, Dr. Comer is an Associate Professor of Health Sciences and Medicine at Indiana University. Dr. Comer is a bioethicists and palliative care researcher who is an expert in medical decision making with a focus on hospitalized patients with critical illness. Dr. Comer serves on the Board of Trustees of the International Neuropalliative Care Society and holds an appointment on the Public Policy Committee of the American Academy of Hospice and Palliative Medicine.

Dr. Comer has received numerous awards for her work, including named Indy' Best and Brightest (2024), and receiving an Early Career Achievement award from the Indiana University School of Law (2018). Her teaching has been recognized through receipt of the Indiana University Trustees Teaching Award (2023) as well as the Indiana University School of Health and Human Sciences Emerging Teaching Award (2018). Dr. Comer was selected as an American Academy of Hospice and Palliative Medicine Research Scholar (2018).

Patricio Santillan-Doherty

Professor, thoracic surgery and bioethics
Faculty of Medicine-UNAM (National Autonomous University of Mexico)
Head of the National Bioethics Commission

Thoracic surgeon and Head, Dep. of Experimental Surgery, National Institute of Respiratory Diseases (1992-1997). Thoracic surgery consultant and Head Dept of Experimental Surgery, National Institute of Medical Sciences and Nutrition Salvador Zubiran (1997-2013). Member, secretary and president of the Committee on Research Ethics at the National Institute of Medical Sciences and Nutrition Salvador Zubiran (2000-2012).

Medical Director, National Institute of Respiratory Diseases. México City (2013-2022).

Member of the National Academy of Medicine of Mexico and the Mexican Academy of Surgery. Member of the Colegio de Bioética (past president 2015-2021). Member of the Nationa Investigators System.

Major General (ret.) Paul Friedrichs, MD

Deputy assistant to the president
Director, Office of Pandemic Preparedness and Response Policy (OPPR)
The White House

Dr. Paul Friedrichs currently serves as Deputy Assistant to the President and as the inaugural Director of The White House Office of Pandemic Preparedness and Response Policy. In this role, Paul coordinates U.S. government efforts to enhance the United States and its partners' ability to prepare for and respond to pandemics and other biological events. Paul previously served as Special Assistant to the President and Senior Director for Global Health Security and Biodefense at the White House National Security Council, where he coordinated U.S. policy to detect, prevent, prepare for, and respond to, infectious diseases and biological threats.

Paul concluded a 37-year military career by serving as the Joint Staff Surgeon at the Pentagon, where he provided medical advice to the Chairman of the Joint Chiefs of Staff on Department of Defense (DOD) operations and served as the medical advisor to the DOD COVID-19 Task Force. He was also the U.S. representative to the North Atlantic Treaty Organization's Committee of the Chiefs of Military Medical Services. In addition to caring for patients in combat, Antarctica and other austere locations, he has led DOD's global medical evacuation system and assisted in multiple major domestic and international responses to natural disasters and biological outbreaks, as well as multiple global health engagements. As Chair of the Military Health System's Joint Task Force on High Reliability Organizations, Paul oversaw development of a roadmap to continuously improve care for more than 9 million service members, retirees and their dependents.

Paul received his commission at Tulane University through the Reserve Officer Training Corps in 1986 and his Doctor of Medicine degree (M.D.) from the Uniformed Services University in 1990. He was a Distinguished Graduate of the National War College, where he received a Master's Degree in Strategic Security Studies and also received an honorary Doctorate in Science from the University of Nebraska Medical Center. He has commanded multiple medical units, served as an Assistant Professor of Surgery and led joint and interagency teams which earned numerous awards. He has been awarded the Defense Distinguished Service Medal, the Bronze Star and has been named a Chevalier in the French Ordre National du Mérite.

Melissa (Missy) Heidelberg, BS, MBE

Bioethics and technology ethics lead; Digital ethics & compliance chief of staff
Takeda Pharmaceutical Company Limited

Missy is a mission-based, socially conscious biopharmaceutical bioethicist with a passion for evolving and implementing ethical frameworks at the intersection of bioethics, data ethics, digital/technology ethics and policy in clinical research and drug development to benefit patients and society. She has over 20 years of experience in drug development and believes the life sciences industry has tremendous opportunity and responsibility to advance science for better health while maintaining ethical obligations to patients.

At Takeda, Missy leads the strategy, evaluation, and integration of bioethics and technology ethics into policies, positions, processes, initiatives, and consultations. This includes chairing the Takeda Ethics Advisory Council (TEAC), which brings together external ethics experts and internal senior leaders to develop ethical guidance for priority topics in bioethics, technology ethics, and responsible innovation. She represents Takeda in multiple industry and professional associations that promote bioethics and ethical behavior in life sciences. She also remains active in the Columbia University Bioethics Master's Program and is a parent representative for the International Rare Diseases Research Consortium (IRDiRC) Task Force focusing on developing a "Framework to assess impacts associated with diagnosis, treatment, support, and community integration". Missy is truly honored to be a panelist at the North American Regional Meeting on the World Medical Association's Declaration of Helsinki in Washington, DC.

Julie Kaneshiro, MA

Acting director
Officer for Human Research Protections
U.S. Department of Health and Human Services

Julie Kaneshiro is the Acting Director of the Office for Human Research Protections (OHRP), and has been the Deputy Director of OHRP since 2014. Her recent work has focused on the revisions to the Common Rule, ethical and regulatory issues related to standard of care research, deceased donor intervention research, and the ethics of mandatory research biopsies. Prior to joining OHRP she worked at the National Institutes of Health for over ten years and worked with the Office for Civil Rights and the Office of the Assistant Secretary for Planning and Evaluation where she assisted in drafting the HIPAA Privacy Rule. Ms. Kaneshiro received her undergraduate degree in English Literature from the University of Maryland in 1991, and her graduate degree in Public Policy with Concentrations in Philosophy and Social Policy (M.A.) from George Washington University in 1996.

Nancy Kass, ScD

Phoebe R. Berman Professor of Bioethics and Public Health
Johns Hopkins University

Nancy Kass, ScD, is the Phoebe R. Berman Professor of Bioethics and Public Health at Johns Hopkins, where she is also both the Deputy Director for Public Health in the Berman Institute of Bioethics and Professor of Health Policy and Management in the Johns Hopkins Bloomberg School of Public Health.

Dr. Kass conducts empirical work in bioethics and health policy. Her publications are primarily in the field of U.S. and global research ethics, HIV/AIDS ethics policy, public health ethics, and ethics and the learning healthcare system. From June 2023-June 2024 she served as Ethics Advisor, Office of the Commissioner, at the Food and Drug Administration through an Intergovernmental Personnel Act (IPA) arrangement. From 2017-2023 Dr. Kass served as Vice-Provost for Graduate Education for Johns Hopkins University. In 2009-2010, Dr. Kass was based in Geneva, Switzerland, working with the World Health Organization (WHO) Ethics Review Committee Secretariat. Dr. Kass is an elected member of the National Academy of Medicine and an elected fellow of the Hastings Center.

Otmar Kloiber, MD

Secretary general
World Medical Association

Dr Otmar Kloiber was appointed as Secretary General of the World Medical Association (WMA) in February 2005. Before joining the WMA, Dr Kloiber served as Deputy Secretary General of the German Medical Association. As WMA Secretary General, he is the head of its Secretariat and is responsible for managing and directing the WMA staff and the activities of the WMA. He provides overall leadership and strategic direction to the organisation and represents the WMA to the Association's members, the medical profession, the international community, representatives of government, the business community, and the public.

Chieko Kurihara, BA

Specially appointed professor
Kanagawa Dental University

Chieko Kurihara, BA, Ethics Working Group of the International Federation of Pharmaceutical Physicians and Pharmaceutical Medicines Development (IFAPP); Specially appointed Professor at Kanagawa Dental University; and Vice-Chair of the Certified Review Board/Senior Researcher at the National Institutes for Quantum Science and Technology, Japan. Editor of a Japanese medical journal Clinical Evaluation; a founding co-representative of the Center for Bioethics Policy Study, a non-profit academic study group. After graduation from the Department of Economics, School of Political Science and Economics, Waseda University in 1983, she has been engaged in journalistic and artistic works, and then in bioethics, especially focusing on research ethics. Not only Task Groups on GCP regulations designated by the Ministry of Health, Labour and Welfare, Japan, she has been engaged in developing international ethics documents and literatures as a member of several Task Groups of the International Commission of Radiological Protection (ICRP), as well as Ethics Working Group of the IFAPP. Since the time of the 2000 revision of the Declaration of Helsinki (DoH), she has published substantial number of peer-reviewed papers, interview articles, proceedings of discussion meetings, and most recently a book titled "*Ethical innovation for global health: pandemic, democracy and ethics in research*" (Springer; 2023), including chapters on patient/public opinions on the DoH, as well as historical analysis on ethics of placebo-controlled study and post-trial access considering pandemic experience.

Susan Marlin

President and CEO
Clinical Trials Ontario

Susan Marlin is the President and CEO of Clinical Trials Ontario (CTO), an organization supported by the Province of Ontario. CTO's flagship program is its streamlined research ethics review program, supporting single research ethics review for multi-site studies. Prior to joining CTO served as the Associate Vice-Principal at Queen's University. Susan worked with the Canadian Cancer Trials Group for many years coordinating clinical trials and leading the development and implementation of the Ethics and Regulatory Office.

Susan has actively engaged in research ethics for many years. She served as President of the Canadian Association of Research Ethics Boards, as a member of the Canadian Institutes of Health Research (CIHR) Research Integrity Committee, the Ontario Cancer Research Ethics Board and the Tri-Agency Panel on the Responsible Conduct of Research. She is an Adjunct Lecturer at Queen's University in Kingston, Ontario and is the nominated principal investigator on a Canadian Institutes of Health Research funded project to streamline research ethics review for child health research across Canada.

Hilary Marston, MD, MPH

Chief medical officer
U.S. Food and Drug Administration

Hilary Marston, M.D., M.P.H., Chief Medical Officer, FDA, serves as the primary clinical advisor to the Commissioner and oversees the Office of Clinical Policy and Programs. She leads cross-cutting initiatives that support the FDA's centers in making effective, safe, and innovative medical products available for patients.

Dr. Marston previously served as the Senior Advisor for Global COVID-19 Response on the White House COVID-19 Response Team. Her previous roles also include Director for Medical Biopreparedness and Response at the U.S. National Security Council and Medical Officer and Policy Advisor for Pandemic Preparedness at the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Dr. Marston also served in positions with McKinsey & Company and the Bill & Melinda Gates Foundation.

Dr. Marston trained in Internal Medicine and Global Health Equity at Brigham & Women's Hospital. She completed her M.P.H. at the Harvard T.H. Chan School of Public Health.

Gustavo Ortiz-Millán, PhD

Professor
Institute of Philosophical Research
National Autonomous University of Mexico

Gustavo Ortiz-Millán is research-professor at the Institute of Philosophical Research, National Autonomous University of Mexico (UNAM), and member of the National System of Researchers of Mexico's National Council for Science and Technology. He holds a PhD in philosophy from Columbia University in New York. He has taught philosophy at Columbia University, New York University, Brooklyn College, and UNAM. He has also been a visiting researcher at the University of California at Berkeley, Duke University and Oxford University. He has been a Fulbright Scholar twice. He is the author of the books *The Morality of Abortion, and Abortion, Democracy and Empowerment,* both of them published in Spanish. He has co-edited several books, the most recent of which are *Mind, Language, and Morality* (with J. Cruz, Routledge, 2018) and *COVID-19 and Bioethics* (in Spanish, with M. Medina, UNAM Press, 2021). He is also the author of more than 100 peer-reviewed articles, book chapters and critical book reviews. His articles have appeared in journals such as the *Journal of Medicine and Philosophy, Cambridge Quarterly of Healthcare Ethics, Journal of Bioethical Inquiry, Global Bioethics, International Journal of Gynecology and Obstetrics, International Journal of Health Policy and Management, Revista de Bioética y Derecho, Indian Journal of Medical Ethics, Dilemat*a, among others. He has also published on topics of metaethics, moral psychology and epistemology.

Academia webpage: https://unam.academia.edu/GustavoOrtizMillan

Jonathan D. Moreno, PhD

Daivd and Lyn Silfen University Professor Emeritus
University of Pennsylvania and
Advisor, Center for Health, Ethics and Society
University of Hamburg

Jonathan D. Moreno is the David and Lyn Silfen University Professor Emeritus at the University of Pennsylvania and an advisor for the Center for Health, Ethics and Society at the University of Hamburg, Germany.

He is a member of the National Academy of Medicine, a fellow the Hastings Center, a member of the Philadelphia College of Physicians, a fellow of the New York Academy of Medicine, a faculty affiliate of the Kennedy Institute of Ethics at Georgetown University, and a member of the Committee on Human Rights of the National Academies of Science, Engineering and Medicine.

Peter Pronovost, MD, PhD, FCCM

Chief quality & clinical transformation officer, University Hospitals
Professor, Department of Anesthesiology and Critical Care Medicine
Case Western Reserve
The Veale Distinguished Professor in Leadership and Clinical Transformation

Peter Pronovost, MD, PhD, is a world-renowned patient safety champion, innovator, critical care physician, a prolific researcher (publishing over 800 peer review publications), entrepreneur (founding a healthcare start-up that was acquired), and a global thought leader, informing US and global health policy. His scientific work to reduce catheter-related bloodstream infections has saved thousands of lives and earned him high-profile accolades, including being named one of the 100 most influential people in the world by *Time Magazine*, receiving a coveted MacArthur Foundation "genius grant" in 2008. Dr. Pronovost currently serves as the Chief Quality & Clinical Transformation Officer for University Hospitals, Cleveland, a comprehensive health system with a national reputation for providing world class healthcare, research and education with annual revenues of $4.4 billion, 20 hospitals, more than 50 health centers and outpatient facilities, and over 200 physician offices located throughout 16 counties.

As Chief Quality & Clinical Transformation Officer, Dr. Pronovost is charged with fostering ideation and implementation for new protocols to eliminate defects in value and thereby enhance quality of care; developing new frameworks for population health management for UH's more than one million patients; and managing the UH Accountable Care Network comprising more than 581,000 members. In this role, Dr. Pronovost leads the system in championing a new narrative that focuses on *Keeping People Healthy at Home*. He created a new list of key principles for eliminating defects in value and has incorporated the framework into an analytic platform integrating claims, electronic medical record (EMR), and scheduling data, to make defects in value visible to clinicians. In just 12 months, this work fueled a reduction in annual costs per patient in the UH ACO by 9 percent. Dr. Pronovost also serves as a Professor in the Department of Anesthesiology and Critical Care Medicine at the Case Western Reserve University School of Medicine and School of Nursing.

Jack Resneck Jr., MD

Former president
American Medical Association

Dr. Jack Resneck Jr., a nationally recognized leader in health policy from the San Francisco Bay Area, was the 177th president of the American Medical Association. A passionate advocate for patients and physicians, he is a prominent spokesperson for advancing quality care, innovation, and public health, and he is a champion for a more equitable health care system.

Dr. Resneck is the Bruce U. Wintroub Endowed Professor and Chair of the UCSF Department of Dermatology and holds a joint appointment as an affiliated faculty member at the Philip R. Lee Institute for Health Policy Studies. He has a long and decorated record of service in organized medicine, including as an AMA Trustee from 2014-2022 and serving as AMA Board chair in 2018-2019. He served on the boards of the National Quality Forum and the American Academy of Dermatology.

Dr. Resneck currently chairs the World Medical Association's process to revise the Declaration of Helsinki. He also serves as Chair of Finance and Planning for the World Medical Association Council. He is active in health services research, and his studies on patient access to care, health care delivery, digital medicine, and public health have been published in prominent journals and attracted national media attention.

Raised in Louisiana, Dr. Resneck received his BA in public policy from Brown University and his MD from UCSF—where he also completed his internship in internal medicine, residency in dermatology and fellowship in health policy.

Lainie Ross, MD, PhD

Dean's professor and inaugural chair
Department of Health Humanities and Bioethics
Professor, Departments of Pediatrics, Neurology, and Philosophy
Director, Paul M Schyve MD Center for Bioethics
University of Rochester

Lainie Friedman Ross, MD, PhD, a pediatrician and philosopher, is the Dean's Professor and Inaugural Chair of the Department of Health Humanities and Bioethics, and the Director of the Paul M Schyve, MD Center for Bioethics at the University of Rochester School of Medicine and Dentistry where she also holds secondary appointments in the Departments of Philosophy, Pediatrics, and Neurology. Dr. Ross is a graduate of Princeton University (AB from the School of Public and International Affairs), University of Pennsylvania Perelman School of Medicine (MD) and Yale University (MPhil and PhD in Philosophy). She trained in pediatrics at the Children's Hospital of Philadelphia and the Morgan Stanley Children's Hospital of New York-Presbyterian.

Dr Ross' research portfolio addresses ethical and policy issues in organ and tissue transplantation, pediatrics, genetics, research ethics and human subjects protections, and health care disparities. In research ethics, she authored a book entitled *Children in Medical Research: Access v Protection* (Oxford UK: Oxford University Press, 2006). She was the first author of 3 manuscripts published in 2010 in the *Journal of Empirical Research on Human Research Ethics (JERHRE)* that addressed the ethics of community engaged research. These manuscripts were adopted by the national consortium of Clinical and Translational Science Award (CTSA). She was a member of the Department of Health and Human Services Secretary Advisory Committee on Human Research Protections (SACHRP), March 2010-March 2014 and the National Institutes of Health Recombinant DNA Advisory Committee. September 2014-July 2018.

Dr. Ross is a Fellow of the Hastings Center, a John Simon Guggenheim Memorial Foundation Fellow, and a member of the National Academy of Medicine.

Bruce A. Scott, MD

President
American Medical Association

Bruce A. Scott, MD, is the president of the American Medical Association and a member of the Board of Trustees. Prior to this, he was a member of the AMA House of Delegates for over 20 years, serving as speaker and vice speaker and was the young physician member on the AMA Board of Trustees.

Dr. Scott has been president of his county and state medical associations and served on the boards of the Greater Louisville Medical Society and the Kentucky Medical Association (KMA) for over 20 years. As a leader in these associations, he fought for access to care for vulnerable populations, improvement in public health and reduction of administrative burdens in health care. He was awarded the KMA Distinguished Service Award in recognition of his work on behalf of Kentucky's physicians and patients.

Dr. Scott is the president of his six-physician independent private practice group, medical director of a multispecialty ambulatory surgery center and holds a clinical appointment at the University of Louisville School of Medicine. He is board-certified in both otolaryngology and facial plastic surgery.

Jay Shaw, PT, PhD

Research director, artificial intelligence, ethics & health
University of Toronto

Dr. Jay Shaw is Canada Research Chair in Responsible Health Innovation and Research Director of Artificial Intelligence (AI), Ethics & Health at the University of Toronto Joint Centre for Bioethics. Dr. Shaw is an Assistant Professor in the Rehabilitation Sector of the Temerty Faculty of Medicine at University of Toronto, with a cross-appointment to the Institute of Health Policy, Management and Evaluation where he supervises research-focused graduate students. His program of research addresses the ethical and social implications of digital innovations in health care.

Kayte Spector-Bagdady, JD, MBe

Assistant professor, obstetrics and gynecology
Interim co-director, Center for Bioethics and Social Sciences in Medicine
University of Michigan

Prof. Kayte Spector-Bagdady, JD, MBe, is health law and bioethics faculty at the University of Michigan (U-M) Medical School. At U-M she is also on the leadership team of the Center for Bioethics and Social Sciences in Medicine, which won the 2022 American Society for Bioethics & Humanities (ASBH) Cornerstone Award.

She is an Associate Editor of the American Journal of Bioethics and a member of the National Academies' committee on Newborn Screening: Current Landscape and Future Directions. In the past, she was also Chair and lead author of the American Heart Association's "Principles for Health Information Collecting, Sharing, and Use," a member of the ASBH Board of Directors, and an Associate Director for President Obama's Presidential Commission for the Study of Bioethical Issues.

The overarching goal of Prof. Spector's work is improving the governance of secondary research with health data and specimens to increase the accessibility of data and generalizability of advances across diverse communities. To that end, she was the PI of a NHGRI K01 studying how and why geneticists select datasets for their research and is the PI both of an NCTAS R01 on hospitals sharing patient data with commercial entities and a Greenwall Faculty grant on generative AI technologies. She is also an active team scientist and have served as a co-investigator on projects that have collectively received over $200 million in extramural funding. Her recent articles have been published in The New England Journal of Medicine, Science, JAMA, Health Affairs, and Nature Medicine, and her research or expertise has appeared in the NY Times, The Washington Post, The Wall Street Journal, TIME, and CNN.

Johannes JM van Delden

Professor, medical ethics
University Medical Center

Johannes (Hans) van Delden is full professor of medical ethics at the University Medical Center of Utrecht University, the Netherlands. There he also leads the project on patient and public participation in care, education and research. He has worked for many years as a practicing nursing home physician. He has published widely on the practice and ethics of end-of-life decisions, research ethics, and ethical issues in the care for the elderly. He has built a strong research team which has created a strong track record in the ethics of end-of-life decisions, research ethics, and ethics of biomedical innovation. He served as the chair of the International Bioethics Committee of UNESCO. He has also served as the president of the Council of International Organisations of Medical Sciences (CIOMS), and as the chair of the workgroup for the revision of the CIOMS ethical guidelines for biomedical research.